Gynaecological oncology research

We are a leader in local, national and international gynaecological cancer research encompassing basic science, histopathology, molecular genetics, surgical innovation, peri-operative care, medical oncology, psycho-oncology and survivorship. 

We aim to attract students and fellows from Australia and overseas who wish to undertake doctoral and post-doctoral research, and encourage collaboration between clinicians and research scientists to deliver new and improved treatments to provide unparalleled care to our patients.
Given the large number of patients seeking treatment for gynaecological cancers at St John of God Subiaco Hospital, we are well placed to undertake translational research. 

The Gynaecological Cancer Research Group includes scientists, clinical researchers and clinicians who are members of a multidisciplinary team that delivers state wide comprehensive patient care.

Our research aims to improve the outcomes and quality of life of women with gynaecological cancers.
  • The third most commonly diagnosed cancer in women in Australia is gynaecological cancer, including ovarian, endometrial, cervical and vulval cancers.
  • Gynaecological cancers, including ovarian, endometrial, cervical and uterine cancers, are the third most commonly diagnosed cancer in women in Australia.
  • Gynaecological cancer research will help improve outcomes and survival rates as well as improve detection, education and quality of life for gynaecologic cancer survivors.
  • Attracting the best clinicians and research scientists to our group will deliver new and improved treatments to patients.
  • Serving as a national recruiting site for surgical trials and novel chemotherapy drug trials to treat women with gynaecological cancers.
  • Improving patient care and outcomes through the latest gynaecological surgical techniques and innovations, medical oncology services and a range of supportive care.
  • Engaging in translational research using tissue specimens obtained through the Western Australian Gynaecologic Oncology Biospecimen Bank.
  • Supporting population health studies and epidemiology of gynaecological cancers in Western Australia using data linkage.
Director Gynaecological Cancer Research Group, supported by the Jako Group
Dr Paul Cohen MD

Gynaecological Oncologists
Dr Stuart Salfinger
Dr Ganendra Raj Kader Ali Mohan

Dr Adeline Tan
Professor Colin Stewart

Medical Oncologists
Dr Andrew Dean
Dr Martin Buck
Dr Tarek Meniawy

Project Manager
Sanela Bilic

Post-doctoral Research Fellow
Dr Aime Powell PhD

Research Officers
Stephanie Jeffares
Maria Beilin
Kellie Cercarelli

Graduate Research Assistant
Dr Bonnie Zhang

Clinical Trials Pharmacist
Naomi Van Hagen

Cohen, P. A., Jhingran, A., Oaknin, A. & Denny, L. Cervical cancer. Lancet. 2019 Jan 12;393

Maxwell-Smith, C., Hince, D., Cohen, P. A., Bulsara, M. K., Boyle, T., Platell, C., Tan, P., Levitt, M., Salama, P., Tan, J., Salfinger, S., Makin, G., Mohan, G. R. K. A., Jiménez-
Castuera, R. & Hardcastle, S. J. A randomised controlled trial of WATAAP (Wearable Activity Technology And Action-Planning) to promote physical activity in colorectal and endometrial cancer survivors. Psychooncology. 2019 Jul;28(7):1420-1429.

Cohen, P.A., Anderson, L., Eva, L., Scurry, J. Clinical and molecular classification of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019 May; 29(4):821-828.

McNulty, M., Das, A., Cohen, P.A., Dean, A. Measuring response to Neoadjuvant chemotherapy in high-grade serous tubo-ovarian carcinoma: an analysis of the correlation between CT imaging and chemotherapy response score. Int J Gynecol Cancer. 2019 May 15. pii: ijgc-2019-000222. https://doi:10.1136/ijgc-2019-000222 

Binju, M., Padilla, M.A., Singomat, T., Kaur, P., Suryo Rahmanto, Y., Cohen ,P.A., Yu, Y.

Mechanisms underlying acquired platinum resistance in high grade serous ovarian cancer - a mini review. Biochim Biophys Acta Gen Subj. 2019 eb;1863(2):371-378.

Cohen, P.A., Powell, A., Böhm, S., Gilks, C.B., Stewart, C.J.R., Meniawy, T.M., Bulsara, M.,Avril, S., et al (Supplementary 1), Singh N. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and metaanalysis of individual patient data. Gynecologic Oncology. 2019 Aug; 154(2):441-448

Sykes, P., Eva, L., van der Griend, R., McNally, O., Blomfield, P., Brand, A., ... Simcock, B. (2019). Pathological process has a crucial role in sentinel node biopsy for vulvar cancer. Gynecologic Oncology, 153(2), 292-296.

NBCS Collaborators, ABCTB Investigators, kConFab/AOCS Investigators, & Cohen, P. (2019). Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 104(1), 21-34.

Hardcastle, S.J., Hince, D., Jiménez-Castuera, R., Boyle, T., Cavalheri, V., Makin, G., Tan, P., Salfinger, S., Tan, J., Mohan, G.R., Levitt, M., Cohen, P.A., Saunders, C., Platell, C. Promoting physical activity in regional and remote cancer survivors (PPARCS) using wearables and health coaching: randomised controlled trial protocol. BMJ Open. 2019 May 24;9(5):e028369.

Roberts, K., Chong, T., Hollands, E., Tan, J., Mohan, G.R.K.A., Cohen, P.A. Screening for sexual health concerns in survivors of gynaecological cancer. Support Care Cancer. 2019 May 18.